Skip to content
AROG Pharmaceuticals
  • About Us
    • Our Team
    • Company Overview
  • Programs
    • Program Overview
    • AML
    • GIST
  • Patient Resources
  • Careers
  • Press and Publications
  • Contact Us

Peer Reviewed Publications

AML

  1. Zhang H, Savage S, Schultz AR, et al. Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. Nature Communications 2019; 10(1): 244.
  2. Tyner JW, Tognon CE, Bottomly D, et al. Functional genomic landscape of acute myeloid leukaemia. Nature 2018; 562(7728): 526-31.
  3. Smith CC, Lin K, Stecula A, Sali A, Shah NP. FLT3 D835 Mutations Confer Differential Resistance to Type II FLT3 Inhibitors. Leukemia 2015; 29(12): 2390-2.
  4. Galanis A, Ma H, Rajkhowa T, et al. Crenolanib is a Potent Inhibitor of FLT3 with Activity Against Resistance-Conferring Point Mutants. Blood 2014; 123(1): 94-100.
  5. Zhang W, Gao C, Konopleva M, et al. Reversal of Acquired Drug Resistance in FLT3-Mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies. Clin Cancer Res 2014; 20(9): 2363-74.
  6. Smith CC, Lasater EA, Lin KC, et al. Crenolanib is a Selective Type I Pan-FLT3 Inhibitor. Proc Natl Acad Sci U S A 2014; 111(14): 5319-24.
  7. Fathi AT. Emergence of Crenolanib for FLT3-Mutant AML. Blood 2013; 122(22): 3547-8.
  8. Zimmerman EI, Turner DC, Buaboonnam J, et al. Crenolanib is Active Against Models of Drug-Resistant FLT3-ITD-Positive Acute Myeloid Leukemia. Blood 2013; 122(22): 3607-15.

GIST

  1. Blay J-Y, Heinrich MC, Hohenberger P, et al. A randomized, double-blind, placebo-controlled, phase III study of crenolanib in advanced or metastatic GIST patients bearing a D842V mutation in PDGFRA: The CrenoGIST study. J Clin Oncol 2017; 35 (suppl; abstr TPS11080).
  2. von Mehren M, Tetzlaff ED, Macaraeg M, et al. Dose escalating study of crenolanib besylate in advanced GIST patients with PDGFRA D842V activating mutations. J Clin Oncol 2016; 34 (suppl; abstr 11010).
  3. Matro JM, Yu JQ, Heinrich MC, Ramachandran A, Ku N, Mehren Mv. Correlation of PET/CT and CT RECIST response in GIST patients with PDGFRA D842V gene mutations treated with crenolanib. J Clin Oncol 2014; 32:5s (suppl; abstr 10546).
  4. Heinrich MC, Griffith D, McKinley A, et al. Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res 2012; 18(16): 4375-84.
  5. Michael M, Vlahovic G, Khamly K, Pierce KJ, Guo F, Olszanski AJ. Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor. Br J Cancer 2010; 103(10): 1554-61.
  6. Lewis NL, Lewis LD, Eder JP, et al. Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers. J Clin Oncol 2009; 27(31): 5262-9.

Career Opportunities

Learn more about current jobs available with Arog Pharmaceuticals

Learn more

5420 LBJ Freeway, Suite 410 Dallas, TX 75240

Email:info@arogpharma.com

ABOUT US

  • Arog Team
  • Company Overview

Programs

  • AML
  • GIST
  • AROG in the News
  • Conference Presentation
  • Peer Reviewed Publications
  • Patient Resources
  • Careers
  • Contact Us

2018. AROG Pharmaceuticals, INC.

logo
  • About Us
    • Our Team
    • Company Overview
  • Programs
    • Program Overview
    • AML
    • GIST
  • Patient Resources
  • Careers
  • Press and Publications
  • Contact Us